Kết quả tìm kiếm - Martin Reck
- Đang hiển thị 1 - 20 kết quả của 214
- Chuyển đến trang tiếp theo
-
1
What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Bằng Martin Reck
Được phát hành 2012Revisão -
2
-
3
-
4
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer Bằng Leora Horn, Martin Reck, David R. Spigel
Được phát hành 2016Revisão -
5
-
6
Nivolumab plus ipilimumab in non-small-cell lung cancer Bằng Martin Reck, Hossein Borghaei, Kenneth J. O’Byrne
Được phát hành 2019Revisão -
7
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer Bằng John V. Heymach, David H. Harpole, Martin Reck
Được phát hành 2024Carta -
8
-
9
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches Bằng Martin Reck, David P. Carbone, Marina Chiara Garassino, Fabrice Barlési
Được phát hành 2021Revisão -
10
-
11
Anesthetic Influence on Occurrence and Treatment of the Trigemino-Cardiac Reflex Bằng Cyrill Meuwly, Tumul Chowdhury, Nora Sandu, Martin Reck, Paul Erné, Bernhard Schaller
Được phát hành 2015Revisão -
12
-
13
-
14
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Pati... Bằng Jonathan W. Goldman, Peipei Shi, Martin Reck, Luis Paz‐Ares, Andrew Koustenis, Karla Hurt
Được phát hành 2015Artigo -
15
-
16
-
17
Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL) Bằng Natasha B. Leighl, Petr Zatloukal, J. Mezger, Rodryg Ramlau, N. Moore, Martin Reck, Christian Manegold
Được phát hành 2010Artigo -
18
Small cell lung cancer: a slightly less orphan disease after immunotherapy Bằng Jordi Remón, Mihaela Aldea, Benjamin Besse, David Planchard, Martin Reck, Giuseppe Giaccone, Jean‐Charles Soria
Được phát hành 2021Revisão -
19
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts Bằng Martin Reck, Fabrice Barlési, Lucio Crinò, Claudia I. Henschke, Dolores Isla, Susanne Stiebeler, David R. Spigel
Được phát hành 2011Revisão -
20
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? Bằng Sanjay Popat, Christian Grohé, J. Corral, Martin Reck, Silvia Novello, Maya Gottfried, Dejan Radonjic, R. Kaiser
Được phát hành 2020Revisão
Công cụ tìm kiếm:
Các môn học liên quan
Medicine
Internal medicine
Oncology
Cancer
Lung cancer
Chemotherapy
Immunotherapy
Confidence interval
Nivolumab
Hazard ratio
Pathology
Surgery
Cisplatin
Clinical endpoint
Clinical trial
Pembrolizumab
Alternative medicine
Placebo
Biology
Gastroenterology
Carboplatin
Ipilimumab
Randomized controlled trial
Adverse effect
Pemetrexed
Atezolizumab
Cancer research
Phases of clinical research
Environmental health
Epidermal growth factor receptor